Phosphodiesterase-4 inhibitor in the treatment of psoriasis and psoriatic arthritis
Treatment of psoriasis and psoriatic arthritis, especially moderate and severe, represents difficulties. Recently, various methods of molecular medicine have been actively developed, however, targeted therapy deserves special attention, which consists of chemical agents that have specific target as...
Saved in:
Main Authors: | O. Yu. Olisova (Author), D. A. Svistunova (Author), L. M. Chernyavskaya (Author), E. M. Anpilogova (Author) |
---|---|
Format: | Book |
Published: |
State Scientific Center of Dermatovenereology and Cosmetology,
2019-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Apremilast and NB-UVB combination therapy in moderate-to-severe plaque type psoriasis
by: O. Yu Olisova, et al.
Published: (2020) -
Systemic treatment of psoriasis: from methotrexate to biologics
by: Olga Yu. Olisova, et al.
Published: (2020) -
Phosphodiesterase-4 Inhibition in Psoriasis
by: Milakovic M, et al.
Published: (2021) -
Psoriasis and Psoriatic Arthritis in ChildhoodPsoriasis and Psoriatic Arthritis in Childhood
by: Nikolay N. Murashkin, et al.
Published: (2020) -
Phosphodiesterase-4 Inhibition in the Management of Psoriasis
by: Erika L. Crowley, et al.
Published: (2023)